Please ensure Javascript is enabled for purposes of website accessibility
A Clinical Trial Saved My Life. So Why Aren’t More Cancer Patients Enrolling?
gvw_calmatters
By CalMatters
Published 5 years ago on
December 14, 2019

Share

I was 37 years old, and the mother of two children ages 1 and 4, when I was diagnosed with Stage IV inflammatory breast cancer. It is a rare, aggressive form of breast cancer that attacks the lymphatic system around the breast. It is usually fatal, widespread by the time a diagnosis is reached.


Laura Holmes Haddad
Special to CALmatters

Opinion
Initially misdiagnosed as mastitis, a biopsy confirmed that it was cancer that had spread to lymph nodes and a rib, and I started chemotherapy. When my breast tumor was still growing after two rounds of AC chemotherapy, my oncologist said there was nothing more to do.
In that moment, I had no options. I was stunned, to say the least. But one day later, an oncologist at a comprehensive cancer center said he thought a clinical trial might work.
I was terrified at the thought of taking an experimental drug but more afraid of dying. He identified two trials and we waited for an answer. A patient doesn’t just find a trial and enroll as if it is a medical version of college admissions.
The oncologist applies on the patient’s behalf and acceptance is based on myriad factors, including type and stage of disease, prior treatment and a patient’s general health. This is particularly difficult if a patient is in an underserved community or population.
I was ready to sign anything, to go anywhere. Clinical trials can save lives. They are conducted at some hospitals, or clinical-trial sites throughout the U.S. But the trials aren’t necessarily at the hospital or medical institution where the patient is being treated.

I Became Trial Patient #985

Travel costs are rarely, if ever, covered by the drug company or health insurance. This creates an absurdity in the system: a patient may be accepted into a trial but unable to get there to participate, because they have limited incomes and can’t afford the travel costs.

Photo of Laura Holmes Haddad at City of Hope in 2018
Laura Holmes Haddad at City of Hope in 2018. (CalMatters)
The trial for which I was suited was already closed, but 30 days later I was accepted on a compassionate use waiver, or what the FDA calls expanded access. This allows a patient whose life is immediately threatened to receive an “investigational medical product.”
Every week for six months I traveled from the Bay Area to the renowned City of Hope in Southern California, receiving every chemotherapy treatment, blood draw and scan at City of Hope.
I became Trial Patient #985.
The emotional, financial, and physical effects were profound. Total strangers donated airline miles, family donated hotel points, and neighbors helped with babysitting and ballet carpool.
But it worked: after six months the study drug shrunk my tumor enough to make me a surgical candidate. A bilateral mastectomy with 19 lymph nodes removed; a salpingo-oophorectomy; 42 days of radiation therapy; and reconstructive surgery followed.
I remained on 800mg of the study drug every day for almost two years after that. In May 2015 I was declared NED, or no evidence of disease, and remain so to this day, at age 44. I am lucky, I know that.
But tens of thousands of Americans with advanced and/or rare cancers need this kind of luck, too. Fewer than 1 in 20 adult cancer patients in the U.S. enroll in a clinical trial, according to a 2019 study in the Journal of the National Cancer Institute.

The Remedy Is Twofold

That translates to 8% of eligible cancer patients in the U.S. enrolled in a clinical trial. With approximately 1.7 million new cancer cases diagnosed in the U.S. in 2018, according to the American Cancer Society, the need for improved access to trials becomes startling.

Photo of Laura Holmes Haddad’s husband, Munir, daughter Penelope, and son Roman
Laura Holmes Haddad’s husband, Munir, daughter Penelope, and son Roman. (CalMatters)
Patients need education, access and support in the process. The barriers to clinical trial access are numerous and include socioeconomic and structural factors. Most patients don’t know if trials are covered by their insurance, and it can vary depending on the state. In addition, even many local oncologist providers don’t know about current trials.
The remedy is twofold.

  • First, better educate both patients and providers about ongoing clinical trials, how to access them and how they will be covered by most insurances. To patients, trials can be frightening; for providers, the process of finding one can be overwhelming.
  • Second, a stronger connection is needed between regional treatment sites (community practices typically cannot offer trials due to the complexity) and larger comprehensive cancer centers, with coordinated and seamless access to those larger centers given the greater availability of clinical trials conducted there, to open up the door more widely to trials.

This partnership would allow patients to get more information and education and allow institutions and trial sponsors to access more patients.
Without these important changes, today’s cancer patients will be left without promising treatments, and lives will be lost. And tomorrow’s patients will suffer from the lack of important discoveries that come from successfully completed trials.
About the Author 
Laura Holmes Haddad is a cancer-patient advocate speaker living in Marin County, and author of “This is Cancer: Everything you need to know, from the waiting room to the bedroom,” laura@lauraholmeshaddad.com. She wrote this commentary for CalMatters, a public interest journalism venture committed to explaining how California’s Capitol works and why it matters.

DON'T MISS

The Deadly Truth: Record Number of Journalists Killed in 2024

DON'T MISS

CHP K-9 Seizes 50 Pounds of Illicit Mushrooms in Fresno County

DON'T MISS

Saint Agnes to Expand Teaching for Clovis Med School Students

DON'T MISS

Belarus Releases 3 People, Including an American and a Jailed Journalist

DON'T MISS

Need Down Payment Help? Fresno Housing Has $25K for First-Time Homebuyers

DON'T MISS

Pentagon’s New Media Rotation Program Boots NPR, NY Times, NBC News

DON'T MISS

Bredefeld Wants Less Scrutiny for Supervisors’ Discretionary Budget. Pacheco Calls It ‘Ironic.’

DON'T MISS

Senate Confirms Gabbard as Trump’s Director of National Intelligence

DON'T MISS

President Trump and Putin Have Agreed to Start Negotiations to End the Ukraine War

DON'T MISS

Google Calendar Users No Longer See Default Entries for Events Like Pride, Black History Month

UP NEXT

Will ‘Too Many Cooks’ Complicate LA’s Recovery From Deadly Fires?

UP NEXT

I Miss the Old Kanye, Not This Antisemitic Crashout

UP NEXT

This Isn’t the Donald Trump America Elected

UP NEXT

Trump Targets Troubled CA Bullet Train Project. Will He Kill It, Too?

UP NEXT

CA School Test Scores Trail Those of States Newsom Considers Culturally Backward

UP NEXT

A Tale of Two Local Districts: Implementing the CA Classroom Cell Phone Ban

UP NEXT

A Presidency That’s Off the Rails. It Took Only Two Weeks.

UP NEXT

DEI Will Not Be Missed in the Military

UP NEXT

Trump Is Going Woke on Energy

UP NEXT

Why CA Fire Response Could Make or Break These Political Careers

Belarus Releases 3 People, Including an American and a Jailed Journalist

58 minutes ago

Need Down Payment Help? Fresno Housing Has $25K for First-Time Homebuyers

1 hour ago

Pentagon’s New Media Rotation Program Boots NPR, NY Times, NBC News

1 hour ago

Bredefeld Wants Less Scrutiny for Supervisors’ Discretionary Budget. Pacheco Calls It ‘Ironic.’

1 hour ago

Senate Confirms Gabbard as Trump’s Director of National Intelligence

3 hours ago

President Trump and Putin Have Agreed to Start Negotiations to End the Ukraine War

3 hours ago

Google Calendar Users No Longer See Default Entries for Events Like Pride, Black History Month

4 hours ago

Apple Changes Gulf of Mexico to Gulf of America on Maps

4 hours ago

Kevin Durant Becomes 8th in NBA History to Score 30,000 Points

4 hours ago

Too Few Tents Entering Gaza Threatens the Truce. Here’s What’s Happening

4 hours ago

The Deadly Truth: Record Number of Journalists Killed in 2024

Last year marked a grim milestone for journalists worldwide. According to the Committee to Protect Journalists (CPJ), 2024 was the deadliest...

19 minutes ago

19 minutes ago

The Deadly Truth: Record Number of Journalists Killed in 2024

A CHP K-9 seized 50 pounds of illicit mushrooms worth $80,000 during a traffic stop on I-5 in Fresno County, leading to the arrest of Phillip Yoon, 35, of Hayward. (CHP)
51 minutes ago

CHP K-9 Seizes 50 Pounds of Illicit Mushrooms in Fresno County

53 minutes ago

Saint Agnes to Expand Teaching for Clovis Med School Students

58 minutes ago

Belarus Releases 3 People, Including an American and a Jailed Journalist

1 hour ago

Need Down Payment Help? Fresno Housing Has $25K for First-Time Homebuyers

1 hour ago

Pentagon’s New Media Rotation Program Boots NPR, NY Times, NBC News

1 hour ago

Bredefeld Wants Less Scrutiny for Supervisors’ Discretionary Budget. Pacheco Calls It ‘Ironic.’

Tulsi Gabbard, President Donald Trump's choice to be the Director of National Intelligence, arrives to appear before the Senate Intelligence Committee for her confirmation hearing on Capitol Hill Thursday, Jan. 30, 2025, in Washington. (AP/John McDonnell)
3 hours ago

Senate Confirms Gabbard as Trump’s Director of National Intelligence

Help continue the work that gets you the news that matters most.

Search

Send this to a friend